PDF Download
PubReader
Export Citation
Email the Author
Share Facebook
Share Twitter
Cited by 0 Article
Metrics (View:47)
Introduction
The term “probiotics” derived from the Greek meaning “for life” refers to live microorganisms that confer health benefits on the host when administered in adequate amounts (Hill et al., 2014). Early observations by Metchnikoff (1907) and Tissier (1900) suggested that modulation of intestinal microorganisms through diet or beneficial bacteria could improve host health; however, these findings were largely anecdotal and lacked systematic validation. The “probiotics” was later introduced by Lilly and Stillwell (1965) to describe substances that promote the growth of beneficial microorganisms, and scientific interest has expanded substantially since the early 2000s.
In 2001, a joint FAO/WHO expert consultation formally defined probiotics as “live microorganisms which, when administered in adequate amounts, confer a health benefit on the host,” establishing internationally harmonized criteria for their evaluation, safety, and quality (FAO & WHO, 2001). Since then, probiotics have been widely investigated as functional food ingredients, with reported benefits for gut health, immune modulation, mental well-being, and skin homeostasis. In Korea, the Ministry of Food and Drug Safety (MFDS) defines probiotics as live microorganisms that confer health benefits and requires that they be notified or individually approved as functional ingredients, demonstrate efficacy and safety according to health functional food standards, and meet a minimum viable count (e.g., ≥1×108 CFU/g). Currently, 19 probiotic strains are officially notified by MFDS (2020).
Probiotics, increasingly used as functional food ingredients, support intestinal barrier function, modulate immune responses, and improve metabolic regulation, indicating potential benefits in metabolic disorders and inflammatory bowel diseases (Ashrafian et al., 2019). They also influence the gut–brain axis, alleviating depressive symptoms, and promote skin health by reducing inflammation and enhancing barrier function (Rinaldi et al., 2022). Overall, probiotics contribute to digestive health, immune function, mental well-being, and skin homeostasis through modulation of the gut environment and host immunity.
Despite these benefits, probiotics exhibit several important limitations. Their intestinal colonization is often transient and highly host-dependent, with substantial inter-individual variability and strain-specific effects (Hill et al., 2014; Derrien & van Hylckama Vlieg, 2015). Moreover, probiotic administration following antibiotic treatment does not consistently promote microbiota recovery and, in some cases, may delay the restoration of microbial diversity (Zmora et al., 2018). Colonization success cannot be reliably predicted, underscoring the challenges associated with reproducibility and personalized application (Suez et al., 2018).
These limitations highlight the need for alternative or complementary strategies that can deliver consistent functional benefits without reliance on microbial viability or host-dependent colonization.
In comparison with probiotics, postbiotics refer to non-viable microorganisms, their cellular components, and metabolites that exert beneficial physiological effects on the host. Accumulating evidence has shown that heat-treated microbial cells, cell-free culture supernatants, and purified microbial components can confer health benefits despite the absence of microbial viability (Piqué et al., 2019).
Probiotic Efficacy Limitations
Although numerous health-related benefits of probiotics have been reported, growing evidence indicates several scientific and clinical limitations in their mechanisms of action and efficacy.
Probiotics can modulate innate and adaptive immune responses by reducing pro-inflammatory cytokines and enhancing regulatory immune pathways. However, these effects are highly strain-specific, and even closely related strains may exhibit markedly different immunological outcomes (Azad et al., 2018; Duranti et al., 2020). Moreover, host-related factors such as immune status and genetic background contribute to substantial inter-individual variability, limiting the generalizability of probiotic effects. In certain cases, probiotics may elicit unfavorable immune responses in susceptible individuals, underscoring the need for personalized approaches (Zmora et al., 2018).
Clinical studies suggest that probiotic supplementation may improve skin conditions, including atopic dermatitis and skin barrier function. These effects are commonly attributed to modulation of the gut–skin axis. However, most studies have been limited by small sample sizes and short intervention periods. In addition, the underlying mechanisms remain poorly understood, and individual variability in response complicates the establishment of consistent clinical efficacy (Salem et al., 2018; de Pessemier et al., 2021; Shirkhan et al., 2024).
Probiotics have been investigated as modulators of metabolic health, with reported benefits in glycemic control, lipid metabolism and body weight regulation. Nevertheless, outcomes remain inconsistent across studies. Limited intestinal persistence of probiotics and interference with native microbiota recovery may reduce long-term efficacy (Derrien & van Hylckama Vlieg, 2015; Suez et al., 2018). Furthermore, the multifactorial nature of metabolic diseases makes it difficult to isolate probiotic-specific effects (Kristensen et al., 2016).
Concept and Classification of Inactivated Probiotics
Whereas probiotics require viability to confer health benefits, postbiotics provide functional effects independent of microbial survival. Heat-treated probiotic cells, cell-free culture supernatants, and purified cellular components have been shown to exert beneficial health effects, collectively referring to inactivated or non-viable probiotic preparations (Piqué et al., 2019). Based on this concept, the International Scientific Association for Probiotics and Prebiotics (ISAPP) formally defined postbiotics as “preparations of non-viable microorganisms and/or their components that confer a health benefit on the host,” a definition published by Salminen et al. (2021).
Inactivated microorganisms are produced using thermal or non-thermal methods that render cells non-viable while preserving their functional properties (Table 1). These processes yield preparations containing structural components and bioactive substances without requiring microbial viability.
| Method | Description | Advantages | References |
|---|---|---|---|
| Heat-killing | Heating at high temperatures for a defined period (e.g., 100°C for 30 min–2 h) | Preservation of surface proteins; widely used and cost-effective | Kang et al., 2021 |
| Tyndallization | Repeated cycles of mild heating and incubation to eliminate spores | Effective against spore-forming bacteria; relatively mild treatment | Piqué et al., 2019 |
| Non-thermal treatments | High-pressure processing, ultraviolet light, irradiation, ultrasound, etc. | No thermal damage; preservation of functional proteins | Asaithambi et al., 2021 |
| Ohmic heating | Uniform internal heating via electric current passage | Minimal structural damage; rapid processing | Jan et al., 2021 |
Paraprobiotics are defined as non-viable microorganisms or their cellular components that provide health benefits to the host. In contrast, postbiotics represent a broader concept that includes not only inactivated microbial cells but also bioactive metabolites produced during microbial growth or released after cell death (Teame et al., 2020). Although their physiological effects vary by strain, several key components are commonly implicated.
Key bioactive components of inactivated microorganisms contribute to their physiological effects. Cell wall components such as peptidoglycans, lipoteichoic acids, and teichoic acids interact with host immune receptors to modulate immune responses and suppress inflammation, and these activities are preserved after cell death (Taverniti & Guglielmetti, 2011; Saito et al., 2020). In addition, surface-layer (S-layer) proteins and exopolysaccharides (EPS) derived from heat-treated microorganisms enhance intestinal barrier function, inhibit pathogen adhesion, and exhibit antioxidant and anti-inflammatory activities (Lebeer et al., 2010; Szabó et al., 2023).
Nucleic acids released from inactivated microorganisms can activate immune signaling via Toll-like receptor 9 (TLR9) through CpG motifs (Wischmeyer et al., 2016), while microbial metabolites such as short-chain fatty acids (SCFAs) contribute to intestinal homeostasis by regulating luminal pH, supporting epithelial energy metabolism, and reducing inflammation (Kang et al., 2021). Antioxidant activities have also been reported for both extracellular and intracellular components of heat-treated microorganisms, which protect intestinal epithelial cells from oxidative stress (Wu et al., 2014).
Collectively, these findings indicate that inactivated microorganisms can promote host health through their bioactive components independently of viability. In this study, the term “inactivated microorganisms” is used to refer to postbiotics, encompassing both non-viable microbial cells and their associated metabolic products, unless otherwise specified. And for more clarity of terminology we added an overview that clearly differentiates probiotics, paraprobiotics, and postbiotics according to the ISAPP definitions (Table 2).
Physiological Effects of Postbiotics
Postbiotics have been shown, mainly through in vitro studies, to modulate nuclear factor kappa B (NF-κB) signaling and reduce the expression of inflammation-related genes such as interleukin-8 (IL-8). These effects are mediated by the stimulation of macrophages and dendritic cells via TLR pathways, although the magnitude of the response varies depending on the inactivation method and route of administration (Taverniti & Guglielmetti, 2011). Similarly, crystalline S-layer proteins derived from heat-treated Lactobacillus acidophilus were reported in cell-based models to suppress pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α) and IL-6, while enhancing anti-inflammatory IL-10 production (Konstantinov et al., 2008).
In animal models, particularly those of inflammatory bowel disease, heat-inactivated Lactobacillus plantarum and L. rhamnosus reduced pro-inflammatory cytokine production by inhibiting NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways and concurrently preserved intestinal epithelial tight junction proteins, thereby alleviating intestinal inflammation and barrier dysfunction (Teame et al., 2020). Evidence related to human immune responses, largely inferred from ex vivo and translational studies, suggests that inactivated Lactobacillus strains can activate dendritic cells and macrophages and contribute to the balance of T helper (Th)1/Th2 immune responses, although direct clinical evidence remains limited (Teame et al., 2020).
Overall, postbiotics demonstrate immunomodulatory and anti-inflammatory potential across experimental systems, with enhanced safety compared to live probiotics; however, further human intervention studies are required to substantiate their clinical efficacy.
Postbiotics can stimulate immune cells and modulate the gut microbial community in a manner comparable to live probiotics. Through interactions with immune cells in the intestinal mucosa, as demonstrated in in vitro and preclinical studies, they enhance mucosal immunity and increase the expression of tight junction proteins, thereby improving intestinal barrier integrity and reducing intestinal permeability (Taverniti & Guglielmetti, 2011). Heat-treated Lactobacillus rhamnosus with different culture durations restored transepithelial electrical resistance in LPS-induced Caco-2 monolayers, preserved surface-bound proteins and inhibited permeability. Strains cultured for longer periods showed superior efficacy, likely due to higher levels of S-layer proteins, peptidoglycan, and lipoteichoic acid (Xie et al., 2024).
Unlike probiotics, postbiotics do not colonize the intestine but indirectly modulate the gut microbiota. In many published studies indicate that they enhance mucosal defense, inhibit pathogen adhesion, and promote beneficial microbial activity, partly through stimulation of SCFA production and reduction of luminal pH (de Almada et al., 2016; Teame et al., 2020).
Postbiotics improve skin health through immunomodulatory, anti-inflammatory, and antioxidant activities. As the skin functions as an immune organ closely linked to gut health, probiotics and inactivated probiotics have been investigated as adjunctive approaches for regulating skin immunity and alleviating inflammatory skin disorders, mainly based on in vitro and animal studies (Yoshitake et al., 2022). Evidence from cell-based and animal models indicates that postbiotics modulate skin immune responses via TLR 2/4 signaling and suppression of the NF-κB pathway, resulting in reduced production of pro-inflammatory cytokines. In experimental models, heat-killed Lactobacillus plantarum reduced TNF-α and IL-8 while increasing IL-10 (Choi et al., 2017), and inactivated L. rhamnosus GG alleviated atopic dermatitis by suppressing Th2 responses and inducing regulatory T cells (Brembilla et al., 2018). Through clinical study and human epidermal models postbiotics upregulate tight junction proteins in keratinocytes to strengthen the skin barrier and enhance hyaluronic acid production plus ceramide metabolism for improved hydration (Wang et al., 2024; Lee et al., 2025).
In animal studies, gut–skin axis mediated interactions contribute to the alleviation of skin symptoms, as the beneficial effects of postbiotics on gut microbial balance indirectly influence skin health (Kimoto-Nira, 2018). Through preclinical models, heat-treated Lactococcus lactis enhanced antioxidant activity, Th 1 responses, and gut immunity for better skin condition, while inactivated Bifidobacterium bifidum regulated T cell differentiation to decrease inflammatory cytokines and increase Tregs, thereby suppressing systemic and skin inflammation (Kim et al., 2024). Collectively, these findings suggest that components present in inactivated probiotics promote the growth of beneficial gut microbiota and enhance SCFA production, thereby modulating intestinal mucosal immunity and reducing systemic pro-inflammatory cytokines, which ultimately contributes to the alleviation of skin inflammation.
Probiotics used in animal feed have been shown, mainly through livestock feeding trials, to improve productivity and disease resistance; however, their application is limited by reduced viability during storage, environmental instability, and concerns regarding antibiotic resistance genes. As an alternative, postbiotics generated via thermal or physical inactivation processes have emerged, and their suitability as feed additives is being actively evaluated (Lee et al., 2013). In swine and poultry studies, postbiotics have been shown to stimulate intestinal mucosal immunity and inhibit pathogen adhesion, with inactivated Lactobacillus acidophilus suppressing Escherichia coli and Salmonella colonization while promoting beneficial Bifidobacterium and Lactobacillus populations (de Almada et al., 2016). Moreover, broiler feeding experiments demonstrated that heat-killed Bacillus subtilis and Lactobacillus plantarum improved intestinal morphology, enhanced antioxidant capacity, and improved meat quality, concomitant with improved feed conversion ratio and growth performance (Bhattarai et al., 2025; Cui et al., 2025).
Beneficial effects of postbiotics on gut stability and stress mitigation have also been reported in calf feeding and challenge studies. Heat-treated Lactobacillus sakei supported early-life gut stabilization in calves (Sasazaki et al., 2020), while administration of Lactobacillus helveticus postbiotics during the weaning period improved behavioral and physiological stress responses in dairy calves (McNeil et al., 2024). In preweaned Holstein calves challenged with Salmonella typhimurium, supplementation with heat-killed Saccharomyces cerevisiae improved weight gain and feed intake and reduced clinical symptoms and fecal shedding, effects associated with reduced plasma haptoglobin levels and improved intestinal morphology (Harris et al., 2017). Similarly, swine studies reported that Lactobacillus rhamnosus GG postbiotics increased IL-10 and reduced TNF-α expression, indicating anti-inflammatory activity and potential utility in enteritis prevention and recovery (Shu et al., 2024).
Current research, largely based on in vitro and in vivo experimental models, has demonstrated that postbiotics can induce apoptosis in cancer cells and modulate the inflammatory tumor microenvironment, thereby suppressing tumorigenesis. In colon cancer cell line studies, inactivated Lactobacillus casei inhibited cell proliferation and activated caspase-dependent apoptotic pathways (Karimi Ardestani et al., 2019). In addition, clinical investigations in malnourished children reported that postbiotics restored impaired macrophage function and promoted Th1 immune activation, which is essential for anticancer and antibacterial defenses, offering a safe immunomodulatory strategy for immunocompromised individuals or those unable to receive live probiotics (Rocha-Ramírez et al., 2020). Metabolic benefits of postbiotics have been demonstrated primarily through diet-induced obesity animal models. Inactivated Lactobacillus plantarum improved lipid metabolism, enhanced insulin sensitivity, and suppressed adipose inflammation; in high-fat diet–fed mice, supplementation attenuated weight gain, reduced blood glucose, cholesterol, alanine aminotransferase, and aspartate aminotransferase levels, downregulated inflammatory gene expression, and decreased lipopolysaccharide-binding protein levels through improved gut barrier integrity (Yoshitake et al., 2021).
Postbiotics also contribute to the alleviation of anxiety, depression, and stress via gut microbiota modulation and neuroimmune regulation. In stress-induced mouse models, heat-killed Lactobacillus helveticus reduced corticosterone levels, improved stress-related behaviors, and increased brain-derived neurotrophic factor, highlighting its role in gut–brain axis modulation (Maehata et al., 2019). Similarly, in chronic social defeat stress models, inactivated Bifidobacterium breve significantly reduced depression-like behaviors by decreasing pro-inflammatory cytokine expression, reshaping gut microbiota composition, and modulating immune responses along the gut–brain axis (Kosuge et al., 2021). In the context of oral health, in vitro and gingivitis model studies demonstrated that inactivated Lactobacillus rhamnosus inhibited the growth of cariogenic and periodontopathic bacteria (Streptococcus mutans and Porphyromonas gingivalis), reduced oral inflammation, and promoted recovery of oral microbiota diversity (Lin et al., 2022).
Postbiotics exert diverse biological activities without requiring microbial viability, as demonstrated across in vitro, animal, and limited human studies. They exhibit immunomodulatory and anti-inflammatory effects primarily through regulation of NF-κB–related signaling and cytokine production, while offering improved safety compared with live probiotics.
In experimental models, postbiotics enhance intestinal barrier integrity, stimulate mucosal immunity, and indirectly modulate gut microbiota by suppressing pathogen adhesion and promoting SCFA production. Through gut-mediated immune regulation, they also contribute to the improvement of inflammatory skin conditions, as shown in cell-based, animal, and emerging clinical studies. In livestock feeding trials, postbiotics have demonstrated beneficial effects on gut health, stress resilience, and growth performance, supporting their application as stable alternatives to probiotics in animal nutrition. In addition, growing evidence from preclinical studies suggests potential roles in metabolic regulation, gut–brain axis modulation, anticancer activity, and oral health.
Overall, postbiotics represent multifunctional bioactive preparations with broad application potential, although further well-controlled human studies are required to confirm their clinical efficacy.
To facilitate understanding of postbiotic–host interactions, Table 3 integrates pattern recognition receptor-mediated signaling mechanisms with representative physiological outcomes and application areas in food, feed, and clinical contexts.
| Postbiotic component | Host receptor(s) / signaling pathway | Key physiological effects | Application area | References |
|---|---|---|---|---|
| Peptidoglycan | TLR2, NOD2 → NF-κB, MAPK | Immune modulation, suppression of excessive inflammation | Functional foods, immune-supportive products | Taverniti & Guglielmetti, 2011; Saito et al., 2020 |
| Lipoteichoic acid (LTA) | TLR2 → MyD88–NF-κB | Cytokine regulation, immune homeostasis | Functional foods, dietary supplements | Lebeer et al., 2010; Taverniti & Guglielmetti, 2011 |
| S-layer proteins | TLR2, DC-SIGN → NF-κB | Epithelial barrier protection, pathogen exclusion | Gut health foods, clinical nutrition | Konstantinov et al., 2008; Szabó et al., 2023 |
| Exopolysaccharides (EPS) | TLR2, C-type lectin receptors → MAPK | Antioxidant activity, gut barrier enhancement | Functional foods, metabolic health | Lebeer et al., 2010; Teame et al., 2020 |
| Short-chain fatty acids (SCFAs) | GPR41/43 → AMPK activation, HDAC inhibition | Barrier integrity, anti-inflammatory and metabolic regulation | Functional foods, feed additives | Kang et al., 2021 |
| Microbial DNA (CpG motifs) | TLR9 → IRF/NF-κB | Th1 activation, innate immune stimulation | Clinical and immune-supportive applications | Wischmeyer et al., 2016 |
| Inactivated LAB cells | PRR-mediated mucosal signaling | Reduced pathogen adhesion, gut stability | Animal feed | de Almada et al., 2016 |
| Cell wall fragments | NF-κB, MAPK modulation | Improved gut morphology, reduced inflammation | Livestock feed | Bhattarai et al., 2025 |
| Postbiotic metabolites | SCFA-related signaling pathways | Improved feed efficiency, growth performance | Livestock production | Cui et al., 2025 |
Regulatory Considerations for Postbiotics
Regulatory oversight for postbiotics remains limited, and no international legal standard specifically defines them. Nevertheless, regulatory frameworks in major regions emphasize three critical aspects: ingredient approval, health/functional claim substantiation, and quality control. The requirements vary according to product category—food, feed, health functional food (or natural health products), and pharmaceuticals—necessitating clear classification for appropriate regulatory pathways. Table 4 summarizes the regulatory categories, ingredient approval pathways, health claim requirements, and quality control indicators for postbiotics across major countries and regions.
Postbiotics are generally derived from probiotic strains, and approval requires demonstration of strain identity, manufacturing process, and inactivation conditions. In Korea, postbiotics are not recognized as a separate ingredient category under health functional food regulations; manufacturers must provide detailed information on the microbial strain, heat-treatment method, and safety assessment data. In the European Union, the European Food Safety Authority (EFSA) allows use of microbial strains with Qualified Presumption of Safety (QPS) status in food, feed, or as additives, which may include inactivated forms, although postbiotics themselves are not legally defined (EFSA, 2011). In the United States, the Food and Drug Administration (FDA) requires demonstration of GRAS status, while the FTC (Federal Trade Commission) monitors advertising claims to ensure they are substantiated (FDA, 2017). Health Canada permits postbiotics as natural health products (NHPs) if safety and efficacy data are provided, and Japan’s MHLW (Ministry of Health, Labour and Welfare, 1992) requires scientific evidence to support functional or health-related claims.
Health-related or functional claims for postbiotics require scientific substantiation in all major Authorities. To date, EFSA has not approved any postbiotic-specific claims, whereas the FDA, FTC, Health Canada, and MHLW evaluate claims based on clinical or preclinical evidence. Regulatory scrutiny is particularly strict for functional foods, NHPs, and pharmaceuticals compared with general foods or feed.
Even in the absence of legally standardized specifications, recommended quality control measures focus on indicator components such as inactivated cell counts, specific cell wall constituents, or microbial metabolites. Verification of the strain and inactivation process is essential to ensure product safety and reproducibility.
Postbiotics retain functional properties such as immunomodulatory, anti-inflammatory, and antioxidant activities despite microbial inactivation by heat, pressure, or ultraviolet treatment, and are therefore easier to process, store, and transport than probiotics (Maehata et al., 2021). In addition, they present a lower risk of horizontal transfer of antibiotic resistance genes and can be safely applied to vulnerable populations, including immunocompromised individuals and patients (James et al., 2021). As a result of their favorable safety and stability profiles, postprobiotics have been commercialized in several countries (Table 5). In Japan, products containing postbiotics have been marketed for immune enhancement and mood improvement. In the United States, postbiotics have been incorporated into vitamin beverages for antioxidant, anti-inflammatory, and immune-supporting purposes. In Spain, liquid supplements for infants and capsule formulations have been developed to prevent abdominal pain and diarrhea. In Korea, no postbiotic products have yet been commercialized; however, several companies are currently conducting research aimed at product development. In addition, a company supported by the Ministry of SMEs and Startups is developing an individually approved postbiotic for sarcopenia, for which overseas patents have been registered and commercialization is in progress (Kim et al., 2023).
| Product (Company/Country) | Included strain | Application | Reported functions | References |
|---|---|---|---|---|
| LAC-Shield™ (Morinaga Milk Industry, Japan) |
Heat-treated Lacticaseibacillusparacasei MCC1849 | Ready-to-eat foods (miso), confectionery, tofu, etc. | Immune enhancement, common cold prevention, mood improvement | Maehata et al., 2019 |
| Staimune® (Blossom Water, USA) |
Heat-treated Bacillus coagulans GBI-30 6086 | Vitamin beverages | Antioxidant, anti-inflammatory, immune support | James et al., 2021 |
| Colimil® Baby (Humana, Spain) |
Heat-treated Lactobacillus acidophilus HA122 with chamomile and lemon balm | Infant liquid supplement | Relief of infantile colic | Liévin-Le Moal et al., 2007 |
| Lacteol™ (Reig Jofre, Spain) |
Heat-treated Lactobacillus acidophilus LB | Pharmaceutical (capsule/suspension) | Alleviation of infectious diarrhea | Xiao et al., 2003 |
Conclusion
Postbiotics represent a promising class of functional ingredients that retain the physiological activities of beneficial microorganisms while offering enhanced safety, stability, and ease of handling compared with live probiotics. Evidence demonstrates their immunomodulatory, anti-inflammatory, intestinal barrier–protective, and antioxidant effects, supporting applications across functional foods, dietary supplements, animal feed, and cosmetic products. Despite these advantages, broader utilization is limited by incomplete understanding of strain-specific mechanisms, variability in bioactive component preservation, and the absence of standardized regulatory frameworks. Future research should focus on elucidating mechanisms of action, identifying key bioactive components, and conducting large-scale, standardized clinical trials. Establishing clear definitions and regulatory guidance will be essential to ensure product quality, safety, and transparent labeling. Addressing these challenges could enable postbiotics to serve as next-generation functional ingredients, combining the benefits of probiotics with improved safety and versatility.
